Published 19 days ago

Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition

Summary by STAT

The company's drug was generally safe and led to rapid and clinically meaningful improvements in cognition, communication, and sleep.

0 Articles

All

Left

Center

Right

The company's drug was generally safe and led to rapid and clinically meaningful improvements in cognition, communication, and sleep.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated18 days agoBias Distribution

100% Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)